Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
NCT04349280 · GlaxoSmithKline · PHASE1 · terminated · last registry update 2024-04-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Primary investigator withdrew the participant due to an SAE” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-10Phase 3 first posted: AstraZeneca, Tremelimumab + Rilvegostomig (NCT06921785)
- 2025-03-30Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cisplatin (NCT02486718)
- 2025-03-24Phase 3 first posted: Eli Lilly and Company, Olomorasib + Pembrolizumab (NCT06890598)
- 2025-03-04Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Bevacizumab (NCT02839707)
- 2025-02-24Phase 3 first posted: Shandong Cancer Hospital and Institute, Systemic therapy (Continuation of current first-line systemic therapy) + Systemic therapy (Early switch to second-line systemic therapy) (NCT06841172)
- 2025-02-21Phase 3 first posted: Gustave Roussy, Cancer Campus, Grand Paris, SoC-based immunotherapy (+/- chemotherapy) (NCT06840782)
- 2025-01-27Results posted on the registry: National Cancer Institute (NCI), Olaparib + Durvalumab (NCT04538378)
- 2024-12-13Phase 3 first posted: National Cancer Institute (NCI), Ceralasertib + Durvalumab (NCT06732401)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Atezolizumab (NCT06712355)
- 2024-10-17Phase 3 first posted: Bristol-Myers Squibb, BMS-986489 (Atigotatug+Nivolumab) + Atezolizumab (NCT06646276)
- 2024-10-17Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Trastuzumab (NCT04661150)
- 2024-10-09Phase 3 first posted: Alliance for Clinical Trials in Oncology, Cisplatin + Carboplatin (NCT06632327)
- 2024-10-01Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-8068 + Adebrelimab (NCT06618664)
- 2024-07-12Phase 3 first posted: National Cancer Institute (NCI), Durvalumab (NCT06498635)
- 2024-06-21Phase 3 first posted: AstraZeneca, Gemcitabine + Cisplatin (NCT06467357)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Durvalumab (NCT04739800)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT02883062)
- 2024-03-19Results posted on the registry: AstraZeneca, Durvalumab / Tremelimumab Combination Therapy (NCT03837899)
- 2024-03-05Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Cisplatin (NCT03228537)
- 2024-02-28Phase 3 first posted: ETOP IBCSG Partners Foundation, Adjuvant durvalumab (NCT06284317)
- 2024-02-28Phase 3 first posted: Jazz Pharmaceuticals, Zanidatamab + Cisplatin (NCT06282575)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
- 2023-12-12Results posted on the registry: Dana-Farber Cancer Institute, Palbociclib + Fulvestrant (NCT03147287)
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-01Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06112379)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision